Details for Patent: 7,368,460
✉ Email this page to a colleague
Title: | Tropane derivatives useful in therapy |
Abstract: | The present invention provides compounds of the formula: ##STR00001## wherein R.sup.1 is C.sub.3-6 cycloalkyl optionally substituted by one or more fluorine atoms, or C.sub.1-6 alkyl optionally substituted by one or more fluorine atoms, or C.sub.3-6 cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms; and R.sup.2 is phenyl optionally substituted by one or more fluorine atoms, to pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds. |
Inventor(s): | Perros; Manoussos (Sandwich, GB), Price; David Anthony (Sandwich, GB), Stammen; Blanda Luzia Christa (Sandwich, GB), Wood; Anthony (Sandwich, GB) |
Assignee: | Pfizer, Inc. (New York, NY) |
Filing Date: | Oct 03, 2003 |
Application Number: | 10/678,836 |
Claims: | 1. A method of treating HIV infection in a mammal, wherein said HIV infection is modulated by a CCR5 receptor in said mammal, comprising administering to said mammal an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof: ##STR00046## wherein R.sup.1 is C.sub.3-6 cycloalkyl optionally substituted by one or more fluorine atoms, or C.sub.1-6 alkyl optionally substituted by one or more fluorine atoms, or C.sub.3-6 cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms; and R.sup.2 is phenyl optionally substituted by one or more fluorine atoms. 2. A method of treating HIV infection in a mammal, wherein said HIV infection is modulated by a CCR5 receptor in said mammal, comprising administering to said mammal an effective amount of a compound selected from the group consisting of: N-{(1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicycl- o[3.2.1]oct-8-yl]-1-phenylpropyl}cyclobutanecarboxamide; N-{(1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol4yl)-exo-8-azabicyclo[- 3.2.1]oct-8-yl]-1-phenylpropyl}cyclopentanecarboxamide; N-{(1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicycl- o[3.2.1]oct-8-yl]-1-phenylpropyl}-4,4,4-trifluorobutanamide; N-{(1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicycl- o[3.2.1]oct-8-yl]-1-phenylpropyl}-4,4-difluorocyclohexanecarboxamide; and N-{(1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicycl- o[3.2.1]oct8-yl]-1-(3-fluorophenyl)propyl}-4,4-difluorocyclohexanecarboxam- lde; or a pharmaceutically acceptable salt thereof. 3. A method of treating HIV infection in a mammal, wherein said HIV infection is modulated by a CCR5 receptor in said mammal, comprising administering to said mammal an effective amount of N-{(1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicycl- o[3.2.1]oct-8-yl]-1-phenylpropyl}-4,4-difluorocyclohexanecarboxamide or a pharmaceutically acceptable salt thereof. |